ClinicalTrials.gg
CompletedNCT03815812Updated Nov 18, 2023

Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia

A Phase 2 interventional study of IBI306 and placebo in Hypercholesterolemia, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Hypercholesterolemia with a site in China — 10 open to participants now, 17 under way, 10 of them phase 3. Hypercholesterolemia · China.

Enrollment
39th of 53
60 · median 207
Started
2019
with 5 others
Phase 2
6 of 59
none open now
Registered
19th of 59
by date
Lead sponsor
4 of 59
Innovent Biologics (Suzhou) Co. Ltd.

Among the 59 studies in Hypercholesterolemia with a site in China, this one is the 39th largest by enrollment of the 53 interventional ones that give a count, is one of 6 that started in 2019, is one of 6 in phase 2, and was the 19th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

10 of the 59 studies in Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Hypercholesterolemia with a site in China, or all of them as a file.
02

Study summary

IBI306 is a fully human monoclonal antibody that binds proprotein convertase substilisin/kexin type 9 (PCSK-9), preventing its interaction with the low-density lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R recycling and low-density lipoprotein cholesterol(LDL-C)uptake. In phase I study IBI306 was shown to be safe and well tolerated. There was robust reduction in LDL-C, Apo(B), non-HDL-C and lipoprotein (a) in healthy subjects. This study is a randomized, double-blind, placebo-controlled, repeated-dosing, multiple ascending dose trial to evaluate the safety and tolerability of a novel PCSK-9 anti-body, IBI306, in Chinese patients with hypercholesterolemia.

Read the detailed description

A total of 60 patients who meet the criteria for admission and have a clinical diagnosis of hypercholesterolemia and have received statin for at least 4 weeks will be randomized and receive different dose groups of IBI306 or matching placebo. Ascending dose design includes 6 dose levels: 75 mg Q2W, 140 mgQ2W, 300 mg Q4W,420mg Q4W, 450 mg Q6W,and 600 mg Q6W. Total duration of the study per subject is 12 weeks.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must meet all of the following inclusion criteria in order to be included in the study:

    • Provide a signed and dated form;
    • Men or women with an age of 18 to 70 years of age at screening (Inclusive);
    • between18kg/m2 and 30kg/m2(Inclusive);
    • Diagnosis of hyperlipidemia, and taking statins with moderate doses or above for at least 4 weeks;
    • Fasting LDL-C between 100 mg / dl (2.6 mmol / L) and 220 mg / dl (5.7 mmol / L) at screening (Inclusive);
    • Fasting triglycerides ≤ 400 mg (4.5 mmol / L) at screening.

Exclusion criteria

Exclusion Criteria:

  • Subjects who do not meet any of the following exclusion criteria cannot be included in the study:

    • Subject's current statin treatment are stable less than 4 weeks prior to random enrollment
    • (NYHA) III or IV heart failure, or last \<30%
    • Uncontrolled hypertension, defined as repeated measurements confirmed, sitting systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg.
    • Diabetic patients have one of the following conditions;

      1. Known microvascular and macrovascular complications
      2. >7.5% within 4 weeks before screening
    • Moderate or severe renal insufficiency, defined as the estimated \<60 ml / min / 1.73 m2 during screening (calculated using the MDRD formula)
    • Active liver disease or impaired liver function, defined as (AST) or alanine aminotransferase (ALT) > 3 times the normal upper limit () at screening.
    • Have previously undergone liver transplant surgery.
    • Creatine kinase (CK) ≥ 3 times the upper limit of normal (ULN) at screening.
    • At the discretion of the investigator, there are known active infections or major blood, kidney, metabolism, gastrointestinal or endocrine dysfunction.
    • Female subject of not willing to use an acceptable method(s) of effective during treatment with product and for an additional 15 weeks after the end of treatment with investigational product. Male subjects are reluctant to inform their female sexual partners about their participation in the clinical study.
    • Female subject is pregnant or breast feeding, planning to become pregnant or planning to breastfeed during treatment with investigational product and/or within 15 weeks after the end of treatment with investigational product..
    • Subjects have been treated with PCSK9 inhibitors or have participated in other PCSK-9 inhibitor studies
    • Subject has known sensitivity to the study drug and its
    • Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment (for example, alcohol or other substance abuse, unable or unwilling to comply with the agreement or mental illness).
    • Currently receiving treatment in another investigational device or drug study, or less than 30 days before randomization since ending treatment on another investigational device or drug study(s) while participating in this study
    • In the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    IBI306

    Participants received one of 6 dose levels of IBI306 administered as multiple subcutaneous dose

    Drug: IBI306

  • Placebo comparator
    placebo

    Participants received matching placebo dose regimen by subcutaneous injection.

    Drug: placebo

Interventions

  • DrugIBI306

    Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W

  • Drugplacebo

    Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W

06

What researchers measure

Primary outcomes

  1. AEs/SAEs

    • Percentage of participants with adverse events and severity of adverse events from the first dose to the last visit

    Time frame: up to 12 weeks

Secondary outcomes

  1. Tmax

    Time frame: up to 12 weeks

  2. Cmax

    Time frame: up to 12 weeks

  3. area under curve (AUC)

    Time frame: up to 12 weeks

  4. volume of distribution (Vd)

    Time frame: up to 12 weeks

  5. half-life (T1/2)

    Time frame: up to 12 weeks

  6. clearance (CL)

    Time frame: up to 12 weeks

  7. accumulation factor (AR)

    Time frame: up to 12 weeks

  8. changes in blood PCSK-9 concentrations at different time points before and after administration relative to baseline

    Time frame: up to 12 weeks

  9. ADA

    The occurrence of anti-IBI306 antibody (ADA) in serum before and after administration

    Time frame: up to 12 weeks

  10. NAb

    The occurrence of neutralizing antibody (NAb) in serum before and after administration

    Time frame: up to 12 weeks

  11. Percent change in LDL-C from baseline at 12 weeks

    Time frame: baseline and week 12

  12. Changes in LDL-C levels from baseline at 12 weeks

    Time frame: baseline and week 12

  13. Percent change in non-HDL-C cholesterol levels from baseline at 12 weeks

    Time frame: baseline and week 12

  14. Percent change in ApoB from baseline at 12 weeks

    Time frame: baseline and week 12

  15. Percent change in ApoB/ApoA1 ratio from baseline at 12 weeks

    Time frame: baseline and week 12

  16. Percent of patients with a 15% or more decrease in LDL-C levels from baseline at 12 weeks

    Time frame: baseline and week 12

  17. Percent change in Lp(a) from baseline at 12 weeks

    Time frame: baseline and week 12

  18. Percent change in mean LDL-C levels at week 6 and 12 relative to baseline

    Time frame: baseline, week 6 and 12

  19. Percent change in mean ApoB levels at week 6 and 12 relative to baseline

    Time frame: baseline, week 6 and 12

  20. Percent change in mean Lp(a) levels at week 6 and 12 relative to baseline

    Time frame: baseline, week 6 and 12

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, China
08

References and documents

Publications

  • Cui Y, Zhao X, Qi L, Li X, Huang Z, Yang G, Qian L, Deng H, Li H, Huo Y. A Potential Long-Acting LDL-Cholesterol-Lowering PCSK9 Monoclonal Antibody: Randomized, Placebo-Controlled Phase 1 Studies. JACC Asia. 2021 Nov 9;1(3):411-415. doi: 10.1016/j.jacasi.2021.09.002. eCollection 2021 Dec. PubMed 36341216 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Dec 2019, 9 months.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 9 months is close to that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2019
First posted
Jan 24, 2019
StartActual
Mar 7, 2019
Primary completionActual
Dec 25, 2019
CompletionActual
Dec 25, 2019
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03815812
Responsible party
Sponsor
First posted
Jan 24, 2019
Start date
Mar 7, 2019
Primary completion
Dec 25, 2019
Completion
Dec 25, 2019
Last update
Nov 18, 2023

Study contacts

Yiming Cui
principal investigator · Peking University First Hospital
Huo Yong
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafolecimab

Start the discussion